Skip to main content

Table 3 Markers reduction ≥ 20% over baseline and tumor response (R)

From: The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients

 

No-R

n (%)

R

n (%)

p-value

CEA reduction ≥ 20%

No

23 (88.5)

13 (56.5)

0.021

Yes

3 (11.5)

10 (43.5)

CYFRA21-1 reduction ≥ 20%

No

24 (92.3)

9 (37.5)

< 0.001

Yes

2 (7.7)

15 (62.5)

NSE reduction ≥ 20%

No

17 (73.9)

11 (52.4)

0.21

Yes

6 (26.1)

10 (47.6)